OH-PRVEN-OPTCS/CLDGENERA
12.8.2024 14:01:30 CEST | Business Wire | Press release
Proven Optics, a premier IT Financial Management Solution provider, today announced the acquisition of CloudGenera, a provider of innovative cloud financial optimization solutions, furthering its mission to create the industry’s most complete IT financial management application platform. The CloudGenera acquisition is the first of what the company anticipates will be several acquisitions as Proven Optics scales growth and leverages a majority growth investment from Silversmith Capital Partners and strategic investment from ServiceNow.
CloudGenera offers vendor-agnostic IT analytics that equip organizations with the business cases necessary to optimize their technology expenditures. By leveraging advanced AI and machine learning technologies, CloudGenera automates decisions regarding application migration and modernization and significantly improves the accuracy of cloud cost forecasts, thus enhancing IT decision-making processes.
“The acquisition of CloudGenera marks a significant milestone for Proven Optics as we expand our cloud costing product capabilities,” said William Miller, Founding Partner & Co-CEO of Proven Optics. “Together, Proven Optics and CloudGenera will provide a more complete solution that provides our customers with new IT decision analysis capabilities to generate business cases for cloud migration and optimization.”
Proven Optics was founded in 2020 to provide IT and finance leaders with the necessary analytics and insights to make better business decisions by automating the financial management of complex IT budgets. Delivered on the ServiceNow Platform and available in the ServiceNow Store, the Proven Optics Financial Management Application Suite offers additional value for ServiceNow customers looking to add a financial lens to their decision-making.
The acquisition enhances the value that Proven Optics’ customers derive from their investment in ServiceNow as a strategic platform. By offering critical market intelligence, both Proven Optics and CloudGenera customers will benefit from an integrated solution that improves cloud orchestration and decisions related to budgeting and future forecasting, allowing IT finance and cloud teams to manage the entire process within a single workflow and take full advantage of the power of the ServiceNow platform.
“We are excited to join forces with Bill, Ben, and the entire Proven Optics team,” said Brian Kelly, Founder and CEO of CloudGenera who has joined Proven Optics as Executive Vice President of Product. “Together, we will provide customers with a comprehensive set of tools to enhance IT value and facilitate smarter decision-making across their cloud infrastructure.”
About Proven Optics
Proven Optics is a software company that focuses on one thing: Financial Management. Proven Optics helps clients in both IT and finance organizations implement financial management toolsets on the ServiceNow platform, leveraging 20+ years of practitioner experience and 100+ Commercial and Federal implementations. Our solutions enable modernization of financial management functions, providing IT and Finance leaders with the necessary analytics and insights to make better business decisions. For more information or a demonstration of our products, please visit www.provenoptics.com.
About CloudGenera
Founded in 2012, CloudGenera supplies vendor-agnostic IT analytics that arm organizations with the business cases needed to optimize their technology spend. CloudGenera’s proprietary algorithms automate application migration and modernization decisions. For more information visit https://go.cloudgenera.com/.
Proven Optics is helping you move from simplifying and centralizing your IT financials to supercharging your IT financial decision-making and execution.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240812664766/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom